Patents by Inventor Richard S. Blumberg

Richard S. Blumberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190225683
    Abstract: Described herein are novel compositions, targeted therapeutic methods, and assays for neutralizing and/or inhibiting the activity of “oxazole-containing (OxC) compounds,” to prevent or delay the onset of epithelial barrier dysfunction and chronic inflammation associated with various disorders, such as colitis.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 25, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Shankar S. IYER, Thomas GENSOLLEN, Amit GANDHI
  • Publication number: 20190201496
    Abstract: Provided herein, in some aspects, are compositions and methods to inhibit AFP interactions with ?2M and/or Class I-related molecule interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate AFP interactions with ?2M and/or Class I-related molecule in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels is desired to increase immunosuppression or enhance organ regeneration.
    Type: Application
    Filed: September 14, 2017
    Publication date: July 4, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., UNIVERSITY OF OSLO
    Inventors: Richard S. BLUMBERG, Michal PYZIK, Amit GANDHI, Inger SANDLIE, Kine Marita Knudsen SAND, Jan Terje ANDERSEN
  • Publication number: 20190201524
    Abstract: The technology described herein relates to compositions and methods for enhancing the immune response and/or reducing T cell tolerance in a subject. In some embodiments, the technology described herein relates to administering inhibitors of two or more of CEACAM1, PD1, and/or LAP to, e.g., synergistically reduce T cell tolerance.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 4, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG
  • Patent number: 10329315
    Abstract: The invention provides, inter alia, immunoinhibitory glycosphingolipids and immunoinhibitory alpha-galactosylceramides and compositions and preparations thereof, and methods of use thereof including in the treatment of conditions characterized by increased iNKT cells and/or activity.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 25, 2019
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
    Inventors: Dennis L. Kasper, Dingding An, Sungwhan Oh, Richard S. Blumberg, Torsten Olszak, Joana F. Neves
  • Publication number: 20190183964
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Application
    Filed: July 9, 2018
    Publication date: June 20, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. BLUMBERG, Timo RATH, Kristi BAKER, Adam MEZO, Zachary TAYLOR, Kevin MCDONNELL, Rosa Maria Silva Garcia GRENHA
  • Publication number: 20190169290
    Abstract: Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.
    Type: Application
    Filed: June 29, 2018
    Publication date: June 6, 2019
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Kristi Baker, Timo Rath
  • Publication number: 20190135915
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.
    Type: Application
    Filed: April 25, 2017
    Publication date: May 9, 2019
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
  • Publication number: 20180298095
    Abstract: Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between CEACAM family members and TIM family members.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 18, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Yasuyuki KONDO, Amit GANDHI
  • Publication number: 20180291101
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: November 13, 2017
    Publication date: October 11, 2018
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan Dana Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • Patent number: 10046023
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 14, 2018
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin McDonnell, Rosa Maria Silva Garcia Grenha
  • Patent number: 10035858
    Abstract: Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 31, 2018
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. Blumberg, Kristi Baker, Timo Rath
  • Publication number: 20180153986
    Abstract: Described herein are compositions and methods for modulating immune response, which can be upregulated or down regulated by enhancement or inhibition of interactions between CEACAM family members and TIM family members.
    Type: Application
    Filed: April 24, 2015
    Publication date: June 7, 2018
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Yasuyuki KONDO, Amit GANDHI
  • Publication number: 20180021455
    Abstract: Receptor-targeted nanoparticles (R-NPs) are provided for selective transport into and through targeted tissues of therapeutic, prophylactic and diagnostic agents. R-NPs can include polymeric particle, lipid particles, inorganic particles, or a combination thereof with a targeting moiety selective for binding to a receptor on the cells where the agent is to be delivered, where the receptor mediates transcytosis of the nanoparticle into and through the cells. In a preferred embodiment, the targeting moiety is the neonatal Fc receptor. Examples demonstrate Fc-targeted nanoparticles which are actively transported across the intestinal epithelium, providing a route for the oral delivery of nanoparticle encapsulated active agents including peptides such as insulin.
    Type: Application
    Filed: August 31, 2017
    Publication date: January 25, 2018
    Inventors: Eric M. Pridgen, Frank Alexis, Omid C. Farokhzad, Robert S. Langer, Richard S. Blumberg
  • Publication number: 20170327578
    Abstract: Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.
    Type: Application
    Filed: December 20, 2016
    Publication date: November 16, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG, Nalan UTKU
  • Publication number: 20170209529
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Application
    Filed: November 17, 2016
    Publication date: July 27, 2017
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. BLUMBERG, Timo RATH, Kristi BAKER, Adam MEZO, Zachary TAYLOR, Kevin MCDONNELL, Rosa Maria Silva Garcia GRENHA
  • Patent number: 9689044
    Abstract: Provided herein are MiIP-Seq assays and methods for detecting and/or identifying an immune-stimulating microbe in a patient sample. Also provided herein are methods for diagnosing an infectious disease or identifying a previously uncharacterized microbe in a patient sample. The methods and assays described herein are advantageous over existing methods in that they (i) do not require a culture step for microbe expansion, (ii) are not specific for a particular microbe and can be used to identify a previously uncharacterized microbe, and (iii) permits rapid processing due to the lack of a microbe culture step.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: June 27, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Arthur Kaser
  • Publication number: 20170044257
    Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.
    Type: Application
    Filed: April 21, 2015
    Publication date: February 16, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Kristi BAKER, Michal PYZIK, Amit GANDHI
  • Publication number: 20170045528
    Abstract: Described herein are methods, assays and systems for selecting subjects with immune-mediated diseases who would optimally respond to anti-FcRn therapies and administering effective amounts of compositions comprising anti-FcRn agents for treating, inhibiting and/or reducing the symptoms of immune-mediated diseases in subjects.
    Type: Application
    Filed: April 23, 2015
    Publication date: February 16, 2017
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Kristi BAKER, Timo RATH
  • Patent number: 9556271
    Abstract: Provided herein are recombinant monoclonal antibodies and antigen-binding portions thereof useful in inhibiting CEACAM1 in tumor cells, and methods of their use in anti-tumor proliferation and invasiveness therapies, such as the treatment of cancer, particularly pancreatic cancer.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: January 31, 2017
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Yu-Hwa Huang, Nalan Utku
  • Publication number: 20170002073
    Abstract: Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.
    Type: Application
    Filed: November 25, 2014
    Publication date: January 5, 2017
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Kristi Baker, Timo Rath